Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303433 · ClinicalTrials.gov registry record · Phase 4
Namenda to Prevent Post-Operative Delirium
A Phase 4 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00303433 is a Phase 4 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 30 participants.
The verdict
NCT00303433, a Phase 4 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Post Operative Delirium is a common and serious risk of surgery. Delirium, when it occurs is associated with an increased risk of mortality, increase length of stay, and more adverse outcomes in general, including increased risk of higher level of care required at discharge. Namenda, which is currently approved for moderate or severe Alzheimer's disease has a unique mechanism of action than other drugs for this condition. It may have the ability to protect the brain from more severe consequences of hypoxia, or hypoglycemia. Hence it is being looked at in this study to see if it can reduce the incidence and/or severity of delirium post-operatively.
Interventions
- DRUG Namenda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303433
The ClinicalTrials.gov registry entry for NCT00303433 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Namenda is the first listed.
NCT00303433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303433 about?
NCT00303433 is a clinical study titled "Namenda to Prevent Post-Operative Delirium". Post Operative Delirium is a common and serious risk of surgery. Delirium, when it occurs is associated with an increased risk of mortality, increase length of stay, and more adverse outcomes in general, including increased risk of higher level of care required at discharge. Namenda, which is curre...
What is the current status of trial NCT00303433?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2006-03. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00303433?
The interventions under investigation include: Namenda (DRUG).
Who is sponsoring clinical trial NCT00303433?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.